Investigational drug · Phase 2
ALD-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alopecia Areata (AA).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ALD-102"
First trial start
2025
Mar 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALD-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alopecia Areata (AA)
Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ALD-102" as an intervention, largest first.
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia AreataActive, not recruiting
Aldena TherapeuticsIndustry
NCT06826196 · 9 participants · Start Mar 24, 2025 · Primary completion Nov 2026
Drug: ALD-102 Solution · For: Alopecia Areata (AA)
Sites: Thousand Oaks, California; West Lafayette, Indiana; Boston, Massachusetts · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.
Eichler F, Duncan CN, Musolino PL, et al. · N Engl J Med 2024
- Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.
Duncan CN, Bledsoe JR, Grzywacz B, et al. · N Engl J Med 2024
- [Effect of strontium in drinking water on blood pressure and inflammatory function in hypertension mice].
Lin Y, Xin Z, Xia Y, et al. · Wei Sheng Yan Jiu 2023
Also in development for Alopecia Areata (AA)
- IMG-007Phase 23 trials
Inmagene LLC · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.